Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, 24mg 30% Improvement Relative Risk Mortality, 12mg -3% Recovery time, 24mg 19% Recovery time, 12mg 6% Progression, 24mg 33% Progression, 12mg 18% Viral clearance, 24mg -33% Viral clearance, 12mg -18% c19ivm.org George et al. CTRI/2020/05/025068 Ivermectin RCT LATE Is late treatment with ivermectin beneficial for COVID-19? RCT 112 patients in India (June 2020 - February 2021) Lower mortality (p=0.55) and faster recovery (p=0.37), not stat. sig. George et al., Indian J. Hematology and Blood Tr.., doi:10.1007/s12288-022-01546-w Favors ivermectin Favors control
Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial
George et al., Indian Journal of Hematology and Blood Transfusion, doi:10.1007/s12288-022-01546-w, CTRI/2020/05/025068
George et al., Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase.., Indian Journal of Hematology and Blood Transfusion, doi:10.1007/s12288-022-01546-w, CTRI/2020/05/025068
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT with 35 single dose 24mg, 38 single dose 12mg, and 39 SOC hospitalized patients with hematological illnesses in India, showing no significant differences. Results were better for 24mg vs. 12mg for all symptomatic outcomes.
Viral clearance results do not follow the randomization with less than 50% of patients tested at day 7, and no adjusted results are provided. Results were obtained for only 43.8% of ivermectin patients and 56.4% of control patients at day 7 and may not be comparable due to the large difference in the percentage of patients tested. Lower test coverage in the ivermectin group is likely related to faster recovery. Ct 40 for E or S was used for viral clearance which may also have low relevance to infectious disease.
risk of death, 30.4% lower, RR 0.70, p = 0.55, treatment 5 of 35 (14.3%), control 8 of 39 (20.5%), NNT 16, 24mg.
risk of death, 2.6% higher, RR 1.03, p = 1.00, treatment 8 of 38 (21.1%), control 8 of 39 (20.5%), 12mg.
recovery time, 18.7% lower, relative time 0.81, p = 0.37, treatment mean 4.82 (±4.35) n=35, control mean 5.93 (±5.93) n=39, 24mg.
recovery time, 6.2% lower, relative time 0.94, p = 0.78, treatment mean 5.56 (±5.42) n=38, control mean 5.93 (±5.93) n=39, 12mg.
risk of progression, 33.1% lower, RR 0.67, p = 0.41, treatment 6 of 35 (17.1%), control 10 of 39 (25.6%), NNT 12, 24mg.
risk of progression, 17.9% lower, RR 0.82, p = 0.79, treatment 8 of 38 (21.1%), control 10 of 39 (25.6%), NNT 22, 12mg.
risk of no viral clearance, 33.3% higher, RR 1.33, p = 0.50, treatment 10 of 15 (66.7%), control 11 of 22 (50.0%), subset of patients with a large difference between groups, day 7, 24mg.
risk of no viral clearance, 17.6% higher, RR 1.18, p = 0.75, treatment 10 of 17 (58.8%), control 11 of 22 (50.0%), subset of patients with a large difference between groups, day 7, 12mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
George et al., 27 May 2022, Randomized Controlled Trial, India, peer-reviewed, 15 authors, study period June 2020 - February 2021, dosage 24mg single dose, trial CTRI/2020/05/025068.
Contact: biju@cmcvellore.ac.in, maheshmoorthy@cmcvellore.ac.in.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Indian J Hematol Blood Transfus https://doi.org/10.1007/s12288-022-01546-w ORIGINAL ARTICLE Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial Biju George1 • Mahesh Moorthy5 • Uday Kulkarni1 • Sushil Selvarajan1 • Priscilla Rupali2 • D. J. Christopher3 • T. Balamugesh3 • Winsley Rose4 • Kavitha M. Lakshmi1 • Anup J. Devasia1 • N. A. Fouzia1 • Anu Korula1 • Sharon Lionel1 • Aby Abraham1 • Vikram Mathews1 Received: 8 February 2022 / Accepted: 26 April 2022 Ó The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2022 Abstract Repurposed drugs may reduce morbidity and mortality in patients with hematological disorders who develop COVID-19 illness. 112 patients with predominantly hematological illnesses were randomized to receive standard of care, ivermectin 12 mg [Iv 12] or 24 mg [Iv24] for asymptomatic, mild, or moderate COVID 19 illness. Serial respiratory samples for rRT-PCR samples were sent on Day 3, 5 and 7. rRT-PCR negativity and C 2 log10 reduction in viral loads on day 3, 5 and 7 were similar between the 3 treatment groups across all disease categories. Symptom progression occurred in 26 patients [21.6%] with no difference across 3 treatment groups. Twenty-two patients [18.3%] have expired while 98 [81.7%] survived. Survival rates were similar across treatment groups [controls—80.5%, Iv12—77.5%, Iv24— 87.2% respectively]. Overall, poorer survival was seen with moderate illness compared to others [51.6% vs 92.1%; Biju George and Mahesh Moorthy are primary authors. & Biju George biju@cmcvellore.ac.in Mahesh Moorthy maheshmoorthy@cmcvellore.ac.in 1 Department of Haematology, Christian Medical College, Vellore, India 2 Department of Infectious Diseases, Christian Medical College, Vellore, India 3 Department of Pulmonary Medicine, Christian Medical College, Vellore, India 4 Department of Paediatric Infectious Diseases, Christian Medical College, Vellore, India 5 Department of Clinical Virology, Christian Medical College, Vellore, India p = 0.000] and was the only significant risk factor identified on multivariate analysis. In this Phase II randomised trial, single dose of 12 or 24 mg of ivermectin did not reduce viral loads, prevent symptom progression, or reduce mortality in patients with predominantly haematological illnesses who develop mild to moderate COVID 19 illness. Keywords Ivermectin  COVID-19  Symptom progression  Survival
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit